- Home
- DCOY vs XBIO Comparison
DCOY vs XBIO Comparison
Compare DCOY & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DCOY | XBIO |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8M | 5.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DCOY | XBIO |
|---|---|---|
| Price | $0.91 | $2.43 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 6.2M | 25.0K |
| Earning Date | 03-23-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,858,935.00 |
| Revenue This Year | N/A | $1.99 |
| Revenue Next Year | N/A | $20.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.30 |
| 52 Week Low | $0.51 | $1.90 |
| 52 Week High | $52.95 | $13.93 |
Technical Indicators
Market Signals| Indicator | DCOY | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 57.78 |
| Support Level | N/A | $2.20 |
| Resistance Level | N/A | $2.31 |
| Average True Range (ATR) | 0.00 | 0.10 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 0.00 | 90.63 |
Price Performance
Historical ComparisonAbout DCOY Decoy Therapeutics Inc. Common Stock
Decoy Therapeutics Inc is a preclinical-stage biotechnology company developing peptide conjugate drug candidates using machine learning, artificial intelligence tools, and high-throughput synthesis techniques. The company's initial pipeline is focused on respiratory viruses and GI cancers.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.